The present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount
of a TNFalpha blocking agent to a subject in combination with the immune checkpoint inhibitor.